PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of brjcancerBJC HomepageBJC Advance online publicationBJC Current IssueSubmitting an article to BJCWeb feeds
 
Br J Cancer. 1999 February; 79(3-4): 530–534.
PMCID: PMC2362452

Second-line treatment for primary central nervous system lymphoma

Abstract

Failure after first-line treatment was reported in 35–60% of immunocompetent patients with primary central nervous system lymphoma (PCNSL). There are currently no reports focusing on salvage therapy. This review analyses prognostic factors and the efficacy of salvage therapy by focusing on data from papers reporting results of first-line treatment in 355 cases. The study group consisted of 173 patients presenting treatment failure. The interval between failure and death (TTD) was compared for age at relapse (≤60 vs >60 years), type of failure (relapse vs progression), time to relapse (≤12 vs >12 months) and salvage treatment (yes vs no). Median TTD was similar in younger and older patients (P = 0.09). Relapsed patients had a longer TTD than patients with progressive disease (P = 0.002). Early relapse led to a shorter TTD than late relapse (P = 0.005). Median TTD was 14 months for patients who underwent salvage therapy and 2 months for untreated cases (P < 0.00001). A multivariate analysis showed an independent prognostic role for salvage therapy and time to relapse. Age and type of failure had no predictive value. Salvage therapy significantly improves outcome and, possibly, quality of life. As many different treatments were used conclusions cannot be made regarding an optimal treatment schedule. © 1999 Cancer Research Campaign

Keywords: primary central nervous system lymphoma, salvage treatment, brain neoplasms, extranodal lymphomas, non-Hodgkin's lymphoma

Full Text

The Full Text of this article is available as a PDF (75K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Bessell EM, Graus F, Punt JA, Firth JL, Hope DT, Moloney AJ, Lopez-Guillermo A, Villa S. Primary non-Hodgkin's lymphoma of the CNS treated with BVAM or CHOD/BVAM chemotherapy before radiotherapy. J Clin Oncol. 1996 Mar;14(3):945–954. [PubMed]
  • Chamberlain MC, Levin VA. Adjuvant chemotherapy for primary lymphoma of the central nervous system. Arch Neurol. 1990 Oct;47(10):1113–1116. [PubMed]
  • DeAngelis LM, Yahalom J, Thaler HT, Kher U. Combined modality therapy for primary CNS lymphoma. J Clin Oncol. 1992 Apr;10(4):635–643. [PubMed]
  • Di Marco A, Rosta L, Campostrini F, Bonetti A, Palazzi M, Garusi G. The role of radiation therapy in the management of primary non-Hodgkin lymphomas of the central nervous system: clinical study of 10 cases. Tumori. 1986 Dec 31;72(6):565–573. [PubMed]
  • Ferreri AJ, Reni M, Villa E. Primary central nervous system lymphoma in immunocompetent patients. Cancer Treat Rev. 1995 Sep;21(5):415–446. [PubMed]
  • Ferreri AJ, Reni M, Bolognesi A, Verusio C, Villa E. Combined therapy for primary central nervous system lymphoma in immunocompetent patients. Eur J Cancer. 1995 Nov;31A(12):2008–2012. [PubMed]
  • Fine HA, Mayer RJ. Primary central nervous system lymphoma. Ann Intern Med. 1993 Dec 1;119(11):1093–1104. [PubMed]
  • Freilich RJ, Delattre JY, Monjour A, DeAngelis LM. Chemotherapy without radiation therapy as initial treatment for primary CNS lymphoma in older patients. Neurology. 1996 Feb;46(2):435–439. [PubMed]
  • Glass J, Gruber ML, Cher L, Hochberg FH. Preirradiation methotrexate chemotherapy of primary central nervous system lymphoma: long-term outcome. J Neurosurg. 1994 Aug;81(2):188–195. [PubMed]
  • Glass J, Shustik C, Hochberg FH, Cher L, Gruber ML. Therapy of primary central nervous system lymphoma with pre-irradiation methotrexate, cyclophosphamide, doxorubicin, vincristine, and dexamethasone (MCHOD). J Neurooncol. 1996 Dec;30(3):257–265. [PubMed]
  • Gonzalez DG, Schuster-Uitterhoeve AL. Primary non-Hodgkin's lymphoma of the central nervous system. Results of radiotherapy in 15 cases. Cancer. 1983 Jun 1;51(11):2048–2052. [PubMed]
  • Kawakami Y, Tabuchi K, Ohnishi R, Asari S, Nishimoto A. Primary central nervous system lymphoma. J Neurosurg. 1985 Apr;62(4):522–527. [PubMed]
  • Krogh-Jensen M, d'Amore F, Jensen MK, Christensen BE, Thorling K, Pedersen M, Johansen P, Boesen AM, Andersen E. Incidence, clinicopathological features and outcome of primary central nervous system lymphomas. Population-based data from a Danish lymphoma registry. Danish Lymphoma Study Group, LYFO. Ann Oncol. 1994 Apr;5(4):349–354. [PubMed]
  • Lachance DH, Brizel DM, Gockerman JP, Halperin EC, Burger PC, Boyko OB, Brown MT, Schold SC., Jr Cyclophosphamide, doxorubicin, vincristine, and prednisone for primary central nervous system lymphoma: short-duration response and multifocal intracerebral recurrence preceding radiotherapy. Neurology. 1994 Sep;44(9):1721–1727. [PubMed]
  • Letendre L, Banks PM, Reese DF, Miller RH, Scanlon PW, Kiely JM. Primary lymphoma of the central nervous system. Cancer. 1982 Mar 1;49(5):939–943. [PubMed]
  • Ling SM, Roach M, 3rd, Larson DA, Wara WM. Radiotherapy of primary central nervous system lymphoma in patients with and without human immunodeficiency virus. Ten years of treatment experience at the University of California San Francisco. Cancer. 1994 May 15;73(10):2570–2582. [PubMed]
  • Loeffler JS, Ervin TJ, Mauch P, Skarin A, Weinstein HJ, Canellos G, Cassady JR. Primary lymphomas of the central nervous system: patterns of failure and factors that influence survival. J Clin Oncol. 1985 Apr;3(4):490–494. [PubMed]
  • Mendenhall NP, Thar TL, Agee OF, Harty-Golder B, Ballinger WE, Jr, Million RR. Primary lymphoma of the central nervous system. Computerized tomography scan characteristics and treatment results for 12 cases. Cancer. 1983 Dec 1;52(11):1993–2000. [PubMed]
  • Murray K, Kun L, Cox J. Primary malignant lymphoma of the central nervous system. Results of treatment of 11 cases and review of the literature. J Neurosurg. 1986 Nov;65(5):600–607. [PubMed]
  • Neuwelt EA, Goldman DL, Dahlborg SA, Crossen J, Ramsey F, Roman-Goldstein S, Braziel R, Dana B. Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: prolonged survival and preservation of cognitive function. J Clin Oncol. 1991 Sep;9(9):1580–1590. [PubMed]
  • O'Neill BP, O'Fallon JR, Earle JD, Colgan JP, Brown LD, Krigel RL. Primary central nervous system non-Hodgkin's lymphoma: survival advantages with combined initial therapy? Int J Radiat Oncol Biol Phys. 1995 Oct 15;33(3):663–673. [PubMed]
  • Peto R, Pike MC. Conservatism of the approximation sigma (O-E)2-E in the logrank test for survival data or tumor incidence data. Biometrics. 1973 Sep;29(3):579–584. [PubMed]
  • Pollack IF, Lunsford LD, Flickinger JC, Dameshek HL. Prognostic factors in the diagnosis and treatment of primary central nervous system lymphoma. Cancer. 1989 Mar 1;63(5):939–947. [PubMed]
  • Rampen FH, van Andel JG, Sizoo W, van Unnik JA. Radiation therapy in primary non-Hodgkin's lymphomas of the CNS. Eur J Cancer. 1980 Feb;16(2):177–184. [PubMed]
  • Reni M, Ferreri AJ, Garancini MP, Villa E. Therapeutic management of primary central nervous system lymphoma in immunocompetent patients: results of a critical review of the literature. Ann Oncol. 1997 Mar;8(3):227–234. [PubMed]
  • Rodriguez MA, Cabanillas FC, Hagemeister FB, McLaughlin P, Romaguera JE, Swan F, Velasquez W. A phase II trial of mesna/ifosfamide, mitoxantrone and etoposide for refractory lymphomas. Ann Oncol. 1995 Jul;6(6):609–611. [PubMed]
  • Sagerman RH, Cassady JR, Chang CH. Radiation therapy for intracranial lymphoma. Radiology. 1967 Mar;88(3):552–554. [PubMed]
  • Sarazin M, Ameri A, Monjour A, Nibio A, Poisson M, Delattre JY. Primary central nervous system lymphoma: treatment with chemotherapy and radiotherapy. Eur J Cancer. 1995 Nov;31A(12):2003–2007. [PubMed]
  • Schultz C, Scott C, Sherman W, Donahue B, Fields J, Murray K, Fisher B, Abrams R, Meis-Kindblom J. Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: initial report of radiation therapy oncology group protocol 88-06. J Clin Oncol. 1996 Feb;14(2):556–564. [PubMed]
  • Selch MT, Shimizu KT, De Salles AF, Sutton C, Parker RG. Primary central nervous system lymphoma. Results at the University of California at Los Angeles and review of the literature. Am J Clin Oncol. 1994 Aug;17(4):286–293. [PubMed]
  • Shibamoto Y, Tsutsui K, Dodo Y, Yamabe H, Shima N, Abe M. Improved survival rate in primary intracranial lymphoma treated by high-dose radiation and systemic vincristine-doxorubicin-cyclophosphamide-prednisolone chemotherapy. Cancer. 1990 May 1;65(9):1907–1912. [PubMed]
  • Socié G, Piprot-Chauffat C, Schlienger M, Legars D, Thurel C, Mikol J, Ifran N, Brière J, Pene F, Gindrey-Vie B, et al. Primary lymphoma of the central nervous system. An unresolved therapeutic problem. Cancer. 1990 Jan 15;65(2):322–326. [PubMed]
  • Uematsu M, Kondo M, Dokiya T, Oguchi Y, Toya S, Torikata C, Kuribayashi T, Hashimoto S. Primary non-AIDS related brain lymphoma. Patterns of failure following radiotherapy. Acta Oncol. 1992;31(5):551–554. [PubMed]
  • Watne K, Scott H, Hager B, Lindegaard MW, Nome O, Abrahamsen AF, Hirschberg H. Primary malignant lymphoma of the brain. A report of 24 cases from the Norwegian Radium Hospital. Acta Oncol. 1992;31(5):545–550. [PubMed]
  • Woodman R, Shin K, Pineo G. Primary non-Hodgkin's lymphoma of the brain. A review. Medicine (Baltimore) 1985 Nov;64(6):425–430. [PubMed]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK